IPN60340 (ICT01)
First-line unfit Acute Myeloid Leukemia
Phase 1/2Breakthrough Therapy Designation
Key Facts
Indication
First-line unfit Acute Myeloid Leukemia
Phase
Phase 1/2
Status
Breakthrough Therapy Designation
Company
About Ipsen
Ipsen is a well-established French biopharmaceutical company that has evolved from its 1986 founding to become a global leader in specialty care medicines. The company focuses on areas of high unmet medical need across oncology, rare diseases, and neuroscience, with particular expertise in neuroendocrine tumors, rare liver conditions like PBC, and neurological disorders including spasticity. Ipsen's strategy emphasizes targeted innovation and strategic partnerships to accelerate drug development and expand their pipeline. The company has demonstrated strong financial performance with consistent growth and maintains a robust balance sheet to support continued R&D investments and pipeline expansion.
View full company profile